Neogen Corporation (NEOG)
| Market Cap | 1.97B +74.5% |
| Revenue (ttm) | 870.56M -3.9% |
| Net Income | -608.84M |
| EPS | -2.80 |
| Shares Out | 217.67M |
| PE Ratio | n/a |
| Forward PE | 35.73 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,596,271 |
| Open | 9.25 |
| Previous Close | 9.25 |
| Day's Range | 8.90 - 9.25 |
| 52-Week Range | 4.53 - 11.43 |
| Beta | 1.84 |
| Analysts | Buy |
| Price Target | 10.67 (+17.9%) |
| Earnings Date | Apr 9, 2026 |
About NEOG
Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and complementary products to detect dangerous and unintended substances in human food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanita... [Read more]
Financial Performance
In fiscal year 2025, Neogen's revenue was $894.66 million, a decrease of -3.20% compared to the previous year's $924.22 million. Losses were -$1.09 billion, 11491.6% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for NEOG stock is "Buy." The 12-month stock price target is $10.67, which is an increase of 17.90% from the latest price.
News
Neogen’s Listeria Right Now test receives AOAC PTM certification
Neogen (NEOG) announced that its Molecular Detection Assay – Listeria Right Now rapid environmental monitoring test has received AOAC Performance Tested Methods certification, validating the test’s pe...
Neogen's Listeria Right Now™ Test Receives AOAC® Performance Tested Methods℠ Certification
LANSING, Mich.--(BUSINESS WIRE)--Neogen® Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, today announced that its Molecular Detection Assay - Listeria Right Now™ rapid envir...
Neogen Stock Tumbles. Why a Guidance Hike and Earnings Beat Aren't Helping.
Neogen's animal safety business is a drag on earnings in the face of ‘third-party' setbacks.
Neogen Earnings Call Transcript: Q3 2026
Core food safety growth and improved margins offset animal safety supply chain headwinds, leading to raised FY26 revenue guidance. Petrifilm transition and genomics divestiture support future margin expansion and debt reduction.
Neogen reports Q3 adjusted EPS 9c, consensus 5c
Reports Q3 revenue $211.2M, consensus $204.62M. “We continued to make significant progress on our strategic transformation in the third quarter as we look to stabilize and strengthen our core business...
Options Volatility and Implied Earnings Moves Today, April 09, 2026
Today, several major companies are expected to report earnings: Simply Good Foods (SMPL), Neogen (NEOG), BlackBerry (BB), Simulations Plus (SLP), WD-40 Company (WDFC), Beam Global (BEEM), AmpliTech Gr...
Neogen raises FY26 revenue view to $857M-$860M from $845M-$855M
Consensus $850.87M.
Neogen Reports Third Quarter Fiscal Year 2026 Financial Results
LANSING, Mich.--(BUSINESS WIRE)--Neogen® Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, announced its financial results for the fiscal third quarter of 2026 and provided up...
Neogen appoints Stacey as Chief Legal & Compliance Officer
Neogen (NEOG) announced the appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary. Most recently, Stacey served as Chief Legal & Compliance Officer and Secretary
Neogen® Corporation Announces Appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary
LANSING, Mich.--(BUSINESS WIRE)--Neogen Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, today announced the appointment of Jennifer Evans Stacey as Chief Legal & Compliance ...
Neogen to Release Third-Quarter Fiscal Year 2026 Financial Results on April 9, 2026
LANSING, Mich.--(BUSINESS WIRE)--Neogen® Corporation (NASDAQ: NEOG) will issue its third-quarter earnings release before the opening of the market on Thursday, April 9, 2026. Executives from the compa...
Zoetis to acquire Neogen animal genomics business for $160M
Zoetis (ZTS) announced it has entered into a definitive agreement with Neogen (NEOG) to acquire Neogen’s animal genomics business for $160M, subject to customary closing adjustments. The deal is subje...
Neogen Announces Sale of Genomics Business to Zoetis
LANSING, Mich.--(BUSINESS WIRE)--Neogen Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, announced today it has entered into a definitive agreement to sell its global genomic...
Neogen issues voluntary nationwide recall of Hycoat sterile solution
Neogen (NEOG) is voluntarily recalling all lots within expiry of Neogen Vet Hycoat Hyaluronate Sodium Sterile Solution, for use in dogs, cats, and horses, to the veterinarian level. Neogen distributes
Neogen Issues Voluntary Nationwide Recall of Neogen®Vet HYCOAT® Hyaluronate Sodium Sterile Solution
LANSING, Mich.--(BUSINESS WIRE)--Neogen Corporation (NASDAQ: NEOG) is voluntarily recalling all lots within expiry of Neogen®Vet HYCOAT® Hyaluronate Sodium Sterile Solution, for use in dogs, cats, and...
Neogen Transcript: 44th Annual J.P. Morgan Healthcare Conference
A new leadership team is driving a turnaround with a three-stage strategy focused on stabilization, growth, and innovation. The company is refocusing its portfolio, investing in R&D, and expects to divest its genomics division by year-end. Q2 results exceeded expectations, supporting cautious optimism for sustained recovery.
Neogen price target raised to $10 from $6.50 at Piper Sandler
Piper Sandler analyst David Westenberg raised the firm’s price target on Neogen (NEOG) to $10 from $6.50 following the company’s recent earnings release. The firm keeps a Neutral rating on
Neogen price target raised to $12 from $8 at Guggenheim
Guggenheim raised the firm’s price target on Neogen (NEOG) to $12 from $8 and keeps a Buy rating on the shares after the company beat revenue and EBITDA expectations and
Neogen Soars After Earnings Beat and Raised Outlook
Neogen beat earnings estimates, raised its full-year revenue outlook, and has now posted back-to-back post-earnings stock spikes.
Morning Movers: Neogen skyrockets following Q2 results and raised FY26 guidance
Stock futures are under pressure as investors reassess early-2026 optimism. After major indexes hit record highs in recent sessions, profit-taking and risk aversion have taken hold, in part because tr...
Neogen Earnings Call Transcript: Q2 2026
Q2 saw a return to positive core growth and significant margin improvement, prompting raised full-year guidance. Food safety led segment growth, while cost actions and divestitures improved profitability and cash flow. Macroeconomic headwinds persist, but operational execution and leadership changes are driving transformation.
Neogen raises FY26 revenue view to $845M-$855M from $820M-$840M
Consensus $825M. Narrows FY26 adjusted EBITDA view to $175M from $165M-$175M. The company said, “The Company is raising its full-year outlook for fiscal year 2026. Revenue is anticipated to be
Neogen reports Q2 adjusted EPS 10c, consensus 7c
Reports Q2 revenue $224.69M, consensus $208.38M. “I am exceptionally proud of the Neogen (NEOG) team as we have initiated the first phase of our strategic transformation with early work focused
Neogen Announces Second-Quarter 2026 Results
LANSING, Mich.--(BUSINESS WIRE)--Neogen Corporation (NASDAQ: NEOG) announced today the results of the second quarter ended November 30, 2025. “I am exceptionally proud of the Neogen team as we have in...
Neogen appoints Joe Freels as chief commercial officer
Neogen (NEOG) announced the appointments of Joe Freels as senior VP and chief commercial officer, effective January 5. Freels will lead Neogen’s global food safety commercial strategy, including sales...